Lushang Freda PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.1yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares

Jun 21

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Apr 16

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Mar 28

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 04

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Feb 27

CEO

Lushang Freda PharmaceuticalLtd CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Baiqiang Xu	Financial Director	1.1yrs	Veri yok	Veri yok
Hongtao Wang	Accounting Supervisor	no data	Veri yok	Veri yok
Hongyang Zhang	Deputy GM & Secretary	1.1yrs	Veri yok	Veri yok
Deqiang Zheng	Deputy General Manager	1.1yrs	Veri yok	Veri yok
Chunming Gao	Deputy General Manager	1.1yrs	Veri yok	Veri yok
Xixi Dou	Deputy General Manager	1.1yrs	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

46.5yo

Ortalama Yaş

Deneyimli Yönetim: 600223 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
YuHai Su	Independent Director	3.3yrs	CN¥100.00k	Veri yok
Desheng Zhu	Independent Director	3.3yrs	CN¥100.00k	Veri yok
Yuanzhong Lu	Chairman of the Supervisory Board	4.8yrs	Veri yok	Veri yok
Ming Zhou	Director	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600223 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Lushang Freda PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Lushang Freda Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 25, 2024

No independent directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.041 (vs CN¥0.043 in 3Q 2023)

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 16%

Price target decreased by 12% to CN¥10.32

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.061 in 2Q 2023)

Lushang Freda Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares

Lushang Freda Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 25, 2024

First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.13 in 1Q 2023)

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Lushang Life Services Co., Ltd. (SEHK:2376) agreed to acquire Shandong Lujian Property Management Limited from Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) for RMB 4.9 million.

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Investor sentiment deteriorates as stock falls 16%

Lushang Freda Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

New major risk - Financial position

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023

New major risk - Dividend sustainability

Lushang Freda Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Price target increased by 8.1% to CN¥13.52

Price target increased by 7.3% to CN¥13.42

Price target increased by 8.3% to CN¥13.29

Price target decreased to CN¥11.17

Lushang Health Plans to Sell Real Estate Assets to Controlling Shareholder or Affiliates

Price target decreased to CN¥12.27

Third quarter 2022 earnings released: CN¥0.033 loss per share (vs CN¥0.19 profit in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.23 in 2Q 2021)

Price target decreased to CN¥12.87

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to CN¥16.16

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.17 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.18 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥16.10

First quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.06 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.34 in FY 2019)

Lushang Health Industry Development Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021

Investor sentiment improved over the past week

New 90-day high: CN¥14.15

New 90-day high: CN¥12.58

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥9.21

Market bids up stock over the past week

Third quarter earnings released

Lushang Health Industry Development Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥9.66

Earnings released

New 90-day high - CN¥15.60

Lushang Health Industry Development Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş